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REVIEW
Abstract: Some specific features of the 24 h blood pressure (BP) pattern are linked to the
progressive injury of target tissues and the triggering of cardiac and cerebrovascular events.
In particular, many studies show the extent of the nocturnal BP decline relative to the diurnal
BP mean (the diurnal/nocturnal ratio, an index of BP dipping) is deterministic of cardiovascular
injury and risk. Normalization of the circadian BP pattern is considered to be an important
clinical goal of pharmacotherapy because it may slow the advance of renal injury and avert
end-stage renal failure. The chronotherapy of hypertension takes into account the epidemiology
of the BP pattern, plus potential administration-time determinants of the pharmacokinetics
and dynamics of antihypertensive medications, as a means of enhancing beneficial outcomes
and/or attenuating or averting adverse effects. Thus, bedtime dosing with nifedipine
gastrointestinal therapeutic system (GITS) is more effective than morning dosing, while also
reducing significantly secondary effects. The dose-response curve, therapeutic coverage, and
efficacy of doxazosin GITS are all markedly dependent on the circadian time of drug
administration. Moreover, valsartan administration at bedtime as opposed to upon wakening
results in improved diurnal/nocturnal ratio, a significant increase in the percentage of patients
with controlled BP after treatment, and significant reductions in urinary albumin excretion
and plasma fibrinogen. Chronotherapy provides a means of individualizing treatment of
hypertension according to the circadian BP profile of each patient, and constitutes a new
option to optimize BP control and reduce risk.
Keywords: valsartan, ambulatory blood pressure monitoring, dipper, nondipper, hypertension,
chronotherapy, circadian rhythm
Introduction
Blood pressure (BP) and heart rate (HR) are characterized by predictable changes
during the 24 h, for the most part in synchrony with the rest-activity cycle (Lemmer
1992; Hermida et al 2002). This circadian variation in BP represents, on the one
hand, the influence of internal factors such as ethnicity, gender, autonomic nervous
system tone, vasoactive hormones, and hematologic and renal variables (Lemmer
1992; Sica and Wilson 2000). On the other hand, BP is affected by a variety of
external factors including ambient temperature/humidity, physical activity, emotional
state, alcohol or caffeine consumption, meal composition, and sleep/wake routine
(Baumgart 1991; Portaluppi and Smolensky 2000; Hermida et al 2002).
Some specific features of the 24 h BP pattern are linked to the progressive injury
of target tissues and the triggering of cardiac and cerebrovascular events. In particular,
many studies show the extent of the nocturnal BP decline is deterministic of
cardiovascular injury and risk. The reduction of the assumed normal 10% to 20%
sleep-time BP decline (nondipper pattern) is indeed associated with elevated risk of
end-organ injury, particularly to the heart (left ventricular hypertrophy and myocardial
infarct), brain (stroke), and kidney (albuminuria and progression to end-stage renal
failure) (O´Brien et al 1988; Verdecchia et al 1994; Staessen et al 1999; Ohkubo et al
2002). O´Brien and colleagues (1988) reported that nondipper hypertensive subjects
Optimal timing for antihypertensive dosing:
focus on valsartan
Ramón C Hermida1
Diana E Ayala1
Carlos Calvo2
1Bioengineering & Chronobiology
Laboratories, University of Vigo,
Campus Universitario, Vigo, 36200
Spain; 2Hypertension and Vascular
Risk Unit, Hospital Clinico
Universitario, Santiago de
Compostela, 15706 Spain
Correspondence: Ramón C Hermida
Director, Bioengineering and
Chronobiology Labs, E.T.S.I.
Telecomunicación, Campus Universitario,
VIGO (Pontevedra) 36200, Spain
Tel: 34-986-812148 & 34-986-812146
Fax: 34-986-812116
Email: rhermida@uvigo.esTherapeutics and Clinical Risk Management 2007:3(1) 120
Hermida et al
are significantly more likely to suffer a stroke than dippers.
Verdecchia and colleagues (1994) also showed that, after
an average follow-up period of 3.2 years, nondipper
hypertensive patients experienced nearly 3 times as many
adverse cardiovascular events as dippers. More recently,
Staessen and colleagues (1999), summarizing results from
the Syst-Eur trial where nitrendipine was dosed at bedtime,
reported that non-dippers experienced a greater incidence
of stroke and myocardial infarction than the group of persons
who had a normal dipping pattern. Results from this trial
also suggested that nighttime BP was the best predictor of
one’s risk to stroke and myocardial infarction. Moreover,
Ingelsson and colleagues (2006) demonstrated that a
nondipping BP pattern and increased nighttime diastolic BP
(DBP) is a predictor of incident congestive heart failure in
elderly men. These authors also addressed the issue of
whether the loss of nocturnal BP reduction per se or an
increased 24 h BP load causes organ damage. After inclusion
of 24 h ambulatory systolic BP (SBP) and DBP as covariates
in addition to antihypertensive treatment and established
risk factors for congestive heart failure, nondipping and
nighttime DBP remained significant predictors of congestive
heart failure, indicating that the nondipping BP pattern per
se is important.
The evaluation of the data from the Ohasama study
indicated, after an average follow-up of 9.2 years, that a
5% decrease in the decline of nocturnal BP in hypertensive
patients was associated with a 31% increased risk of
cardiovascular mortality (Ohkubo et al 2002). What is even
more relevant, dipper hypertensives had a relative hazard
of cardiovascular mortality similar to that of nondipper
normotensives (Ohkubo et al 2002). These results indicate
that cardiovascular risk could be influenced not by BP
elevation alone, but also by the magnitude of the circadian
BP variability. In keeping with the results from the Syst-
Eur trial, a more recent evaluation of the Ohasama study
has indicated, after 10.8 years of follow-up, that nighttime
BP has a better prognostic value than daytime BP (Kikuya
et al 2005). Accordingly, there is growing interest in how to
tailor the treatment of hypertensive patients according to
their circadian BP pattern (Ohkubo et al 2002; Hermida and
Smolensky 2004).
Because the main steps in the mechanisms regulating
BP are circadian-grade-dependent (Portaluppi and
Smolensky 2000), it is not surprising that antihypertensive
medications may display a circadian time-dependency in
their pharmacokinetics and effects (Lemmer 2000; Hermida
and Smolensky 2004). Chronotherapeutics has been defined
as the purposeful timing of medications to proportion their
serum and tissue concentrations in synchrony with known
circadian rhythms in disease processes and symptoms as a
means of enhancing beneficial outcomes and/or attenuating
or averting adverse effects (Smolensky and Haus 2001).
The chronotherapy of hypertension takes into account the
epidemiology of the day–night BP pattern, plus potential
administration-time determinants of the pharmacokinetics
and dynamics of antihypertensive medications, as a means
of enhancing beneficial outcomes and/or attenuating or
averting adverse effects (Smolensky and Haus 2001).
Specifically, it entails the attenuation of the accelerated
morning rise of SBP and DBP along with the normalization
of elevated daytime, nighttime and 24 h BP means, towards
a dipper BP pattern associated with lower cardiovascular
risk.
Chronotherapy of antihypertensive
medication: effects on the
circadian BP pattern
Appreciable ingestion-time differences in the kinetics (ie,
chronokinetics) of BP-lowering and cardiac medications are
well known (Lemmer and Portaluppi 1997; Smolensky
1997; Lemmer 2000). They result from circadian rhythms
in gastric pH and emptying, gastrointestinal motility, biliary
function and circulation, liver enzyme activity, and blood
flow to the duodenum, kidney and other organs, among other
factors (Labrecque and Beauchamp 2003). Clinically
relevant dosing-time differences in the beneficial and
adverse effects (termed chronodynamics) of BP-lowering
medications are also known. They result from the
chronokinetics of the medications as well as circadian
rhythms in drug-free fraction, rate-limiting steps of key
metabolic pathways, receptor number and conformation and/
or second messenger dynamics (Witte and Lemmer 2003).
Differences in efficacy depending on the time of day of drug
administration lead to differences in effects on the circadian
pattern of BP and, in particular, on the nocturnal decline
relative to the diurnal mean of BP (the diurnal/nocturnal
BP ratio, an index of BP dipping).
Chronotherapy with calcium channel
blockers
Several trials have investigated the differential effects of
morning versus evening administration of calcium channel
blockers (CCB) including amlodipine (Mengden et al 1992;
Nold et al 1998; Qiu et al 2003), cilnidipine (Kitahara et alTherapeutics and Clinical Risk Management 2007:3(1) 121
Optimal timing for antihypertensive dosing
2004), diltiazem (Kohno et al 1997), isradipine (Fogari et
al 1993; Portaluppi et al 1995), nifedipine (Greminger et al
1994; Hermida et al 2005a), nisoldipine (White et al 1999),
and nitrendipine (Meilhac et al 1992; Umeda et al 1994). A
sustained-release formulation of diltiazem was more
effective on the 24 h mean BP when administered at night,
although reducing the diurnal/nocturnal BP ratio towards a
more nondipper profile (Kohno et al 1997). Dihydropyridine
derivatives, differing in pharmacokinetics, seem to reduce
BP homogeneously during day and night independently of
dosing time. While peripheral edema seems to be more
prevalent with dihydropyridine CCB as compared with other
antihypertensive drugs, the incidence of this secondary effect
might be reduced with evening as compared with morning
dosing. The potential reduction of secondary effects with
evening administration of CCB has already been taken into
account in the design of previous trials. In the Syst-Eur trial
mentioned above, where the objective was to investigate if
active treatment (as compared with placebo) could reduce
cardiovascular complications in elderly patients with
isolated systolic hypertension, the studied drug
(nitrendipine) was administered in the evening (Staessen et
al 1999).
There are, however, some exceptions to the general
conclusion that CCB have similar efficacy independently
of dosing time. Umeda and colleagues (1994) reported that
the effect of treatment with nitrendipine on the nocturnal
mean of BP was significantly greater when the drug was
administered in the evening, while also increasing the
diurnal/nocturnal BP ratio towards a more dipper profile.
Similar findings were reported by Portaluppi and colleagues
(1995) who explored the relative advantage of evening
versus morning once-a-day treatment with isradipine on the
nondipping 24 h BP pattern in patients with chronic renal
failure. The findings of this study demonstrated that in those
nondipper chronic renal failure patients an evening, as
compared to a morning, isradipine treatment schedule is
more likely to effectively reduce the 24 h mean SBP and
DBP and to restore the normal nocturnal dipping and
circadian BP patterning.
Chronotherapy with angiotensin-
converting enzyme inhibitors
Clinical studies demonstrated a different effect of the
angiotensin-converting enzyme inhibitors (ACEI)
benazepril (Palatini et al 1993), enalapril (Witte et al 1993),
perindopril (Morgan et al 1997), quinapril (Palatini 1992),
ramipril (Myburgh et al 1995), and trandolapril (Kuroda et
al 2004) when dosed in the morning versus the evening. In
all cases, evening administration of the drugs resulted in a
higher effect on nocturnal BP and a significant modification
of the circadian profile of BP. In a cross-over study on 20
hypertensive patients, Kohno and colleagues (2000) found
no significant differences between the reduction in diurnal
and nocturnal BP means after 10 mg/day imidapril
administered either in the morning or in the evening.
Similarly to most ACEI investigated so far, ramipril was
more effective on the diurnal values of BP when
administered in the morning and more effective on nocturnal
BP when administered in the evening (Myburgh et al 1995).
In the HOPE (Heart Outcomes Prevention Evaluation) study
(Yusuf et al 2000) patients in the active treatment group
received ramipril at bedtime. Results from a small substudy
where patients were evaluated with ambulatory BP
monitoring (ABPM) showed a marked BP reduction
particularly during nighttime sleep (Svensson et al 2001),
thereby reducing the prevalence of nondippers. The authors
concluded that the effects on cardiovascular morbidity and
mortality seen with ramipril in the HOPE study may relate
to effects on BP patterns over the 24 h period (increase in
the diurnal/nocturnal BP ratio) (Svensson et al 2001).
Chronotherapy with α-adrenoceptor
antagonists
Alpha-adrenoceptor blockade more effectively reduces
peripheral resistance in the early morning hours than at other
times of the day (Panza et al 1991). Indeed, a single
nighttime dose of the α-blocker doxazosin reduced both
SBP and DBP throughout day and night, but its greatest
effect was exerted early in the morning (Pickering et al
1994). Interestingly, the peak effect of doxazosin following
nighttime dosing occurred later than predicted based upon
the pharmacokinetic criteria (Pickering et al 1994),
suggesting a circadian stage dependency in the dose-
response relationship, such as previously detected for
nifedipine (Lemmer et al 1991), enalapril (Witte et al 1993),
and propranolol (Langner and Lemmer 1988).
A recent study exploring the administration-time-
dependent effects of the doxazosin gastrointestinal
therapeutic system (GITS) formulation (Hermida et al 2004)
involved 91 subjects with stage 1 or 2 essential hypertension
(Guidelines Committee 2003), randomly assigned to receive
the daily dose of doxazosin GITS (4 mg/day) either upon
awakening or at bedtime for three months. Daily ingestionTherapeutics and Clinical Risk Management 2007:3(1) 122
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of doxazosin GITS upon awakening caused only a small
and nonstatistically significant BP reduction, mainly because
of an absence of drug effect on nocturnal B, thus
significantly reducing the diurnal/nocturnal BP ratio towards
a more nondipper profile. In contrast, daily ingestion of the
medication at bedtime resulted in a statistically significant
BP reduction. In summary, doxazosin GITS ingested daily
upon awakening failed to provide full 24 h therapeutic
coverage, while bedtime dosing significantly reduced BP
throughout the entire 24 h, whether used alone as a
monotherapy or in combination with other antihypertensive
medications (Hermida et al 2004).
In another recent trial, Kamoi and Ikarashi (2005) found
that bedtime administration of doxazosin was safe and
effective in reducing morning hypertension and albuminuria
in patients with type-2 diabetes. On the other hand, the
ALLHAT study (2000) indicated that treatment with
doxazosin increased the risk of stroke and combined
cardiovascular diseases and heart failure (Davis et al 2002).
In this trial, doxazosin was taken once daily in the morning.
Such administration may not be the best preference to
adequately control high BP throughout the 24 h, as
previously documented (Pickering et al 1994; Hermida et
al 2004).
Chronotherapy with ß-adrenoceptor
antagonists
A summary of conventional studies (with drugs administered
without time specification) (Stanton and O´Brien 1994)
showed that ß-blockers either have no effect or reduce the
rhythmic pattern in BP towards a more nondipper profile.
In general, there is a tendency for ß-blockers to
predominantly reduce diurnal BP and not to greatly affect
nighttime values (Stanton and O´Brien 1994; Lemmer and
Portaluppi 1997). In healthy subjects, a crossover study with
propanolol showed a higher decrease in BP and HR during
daytime hours than at night (Langner and Lemmer 1988).
The higher impact of ß-blockers on diurnal than on nocturnal
BP correlates with the circadian rhythm in sympathetic tone,
as indicated by the circadian rhythm in plasma noradrenaline
(de Leeuw et al 1977).
In a recent study, we investigated the administration
time-dependent antihypertensive efficacy of nebivolol in the
presumably first chronotherapy trial with a ß-blocker
(Hermida et al 2005b). In this trial, patients with essential
hypertension were randomly assigned to receive nebivolol
monotherapy (5 mg/day) either on awakening or at bedtime
for two months. The diurnal/nocturnal BP ratio was
significantly reduced towards a more nondipping pattern
only after morning dosing, and was mainly unchanged after
bedtime treatment. Results suggested that dosing time with
nebivolol should be chosen at bedtime, without any loss in
efficacy as compared with the usual morning administration,
but avoiding the reduction in diurnal/nocturnal BP ratio that
seems to be associated with higher cardiovascular risk.
Chronotherapy with angiotensin II
receptor blockers
Angiotensin II receptor blockers (ARB) selectively and
specifically antagonize the action of angiotensin II, a potent
vasoconstrictor impacting BP regulation. ARBs are
becoming increasingly popular because they are effective
and well tolerated (Guidelines Committee 2003). A recent
study (Hermida et al 2003a) used 48 h ABPM to assess the
antihypertensive efficacy of the ARB valsartan when
ingested by stage 1 or 2 essential hypertension patients for
three months, either in the morning after awakening from
nighttime sleep or at bedtime. The highly significant BP
reduction after treatment with 160 mg/day valsartan was
similar for both treatment times. Valsartan administration
at bedtime as opposed to upon awakening, however, resulted
in a highly significant average increase by 6% in the diurnal/
nocturnal BP ratio, corresponding to a 73% relative
reduction from baseline in the number of nondipper patients
(Hermida et al 2003a). The findings suggested the dosing
time of valsartan could be chosen in relation to the dipper
status of a given patient to improve therapeutic benefit and
reduce cardiovascular risk. These results have been recently
corroborated by two independent prospective chronotherapy
trials, the first on elderly hypertensive patients (markedly
characterized by a progressive reduction in diurnal/nocturnal
BP ratio with aging) (Hermida et al 2005c), and the second
on nondipper hypertensive patients (Hermida et al 2005d).
In the first of these trials, we studied 100 elderly patients
with grade 1–2 essential hypertension randomly assigned
to receive valsartan (160 mg/day) either upon awakening
or at bedtime. There was a highly significant BP reduction
after three months of valsartan (p<0.001), slightly larger
with bedtime than with morning dosing. The diurnal/
nocturnal BP ratio was unchanged in the group ingesting
valsartan upon awakening, but significantly increased when
valsartan was ingested at bedtime. Results from this trial
suggest that in elderly hypertensive patients, characterized
by a diminished nocturnal decline in BP, bedtime valsartanTherapeutics and Clinical Risk Management 2007:3(1) 123
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dosing is better than morning dosing since it improves
efficacy during the nighttime sleep span, with the potential
reduction in cardiovascular risk that has been associated
with the normalization of the diurnal/nocturnal BP ratio.
In the second trial, we used a similar design to investigate
the administration time-dependent effects on BP of the same
dose of valsartan (160 mg/day) in a selected population of
nondipper hypertensive patients (Hermida et al 2005d). The
significant BP reduction after three months of treatment was
similar for both treatment times. The diurnal/nocturnal BP
ratio was significantly increased only when valsartan was
administered before bedtime, which resulted in 75% of the
patients in this group reverting to dippers, a significant
increase in the percentage of patients with controlled
ambulatory BP after treatment, and a significant reduction
in urinary albumin excretion (Hermida et al 2005d).
Further evidence on the time-
dependent antihypertensive
efficacy of valsartan
As indicated above, there is growing interest in how to treat
nondipper hypertensive patients, due to their increasing
cardiovascular risk and potential differing response to
treatment as compared with patients with a normal dipping
BP pattern. Some studies have indeed found differential
effects of antihypertensive medications according to the
dipping status of the patients (Ebata et al 1995; Kario and
Shimada 1997; Kohno et al 1999, 2000; Kario et al 2000).
However, efficacy studies of antihypertensive drugs in
selected populations of nondipper patients are scarce.
Accordingly, we have attempted to corroborate earlier
conclusions (Hermida et al 2005d) evaluating the
antihypertensive efficacy of valsartan monotherapy when
dosed either in the morning after awakening from nighttime
sleep or at bedtime for a three-month span in nondipper
hypertensive patients.
Methods
Subjects
This prospective chronotherapy trial was conducted at the
Hypertension and Vascular Risk Unit, Hospital Clínico
Universitario, Santiago de Compostela, Spain. Shift-
workers, heavy drinkers (alcohol intake >80 g/d), smokers
(>20 cigarettes/d), and heavy exercisers were excluded, as
were individuals with either severe arterial (grade 3, that is
BP ≥180/110 mm Hg) or secondary arterial hypertension
and cardiovascular disorders, including angina, heart failure,
stroke, nephropathy, and retinopathy or prior myocardial
infarction or coronary revascularization as revealed by
thorough clinical evaluation according to the standardized
protocol at the Unit. Inclusion criteria required a diagnosis
of grade 1 or 2 essential hypertension according to criteria
of the recent European Society of Hypertension–European
Society of Cardiology guidelines (Guidelines Committee
2003) based on conventional BP measurements (SBP
between 140 mm Hg and 179 mm Hg or DBP between
90 mm Hg and 109 mm Hg) and corroboration by ABPM at
the time of recruitment. A positive diagnosis of hypertension
based on ABPM in this trial required that either the 24 h
mean SBP/DBP be above 130/80 mm Hg, the diurnal mean
be above 135/85 mm Hg, or the nocturnal mean be above
120/70 mm Hg (O´Brien and Staessen 1995; O´Brien et al
2003; Pickering et al 2005). Moreover, inclusion criteria
required all patents to be nondipper (here defined as <10%
decline in nocturnal mean compared with the diurnal mean
of SBP using all data sampled by ABPM for 48 consecutive
hours). With all these inclusion/exclusion criteria we
identified 207 subjects who were accordingly randomized
for the trial. Among these, 200 subjects (78 men and 122
women), 53.9±13.2 years of age, completed the study.
After providing signed informed consent to participate
in this prospective, randomized, open-label, blinded
endpoint (PROBE), parallel-group chronotherapy trial, and
after a 2- to 4-week wash-out period when required (78%
of the participants were previously never treated for
hypertension and an additional 11% were untreated for at
least 6 months), subjects were randomly assigned to receive
single daily valsartan monotherapy (160 mg/day; the highest
recommended and most widely used dose in Spain) either
in the morning on awakening from nighttime sleep or at
bedtime. Benefits of the PROBE design and its validity as
compared with double-blind, placebo-controlled trials, in
assessing antihypertensive efficacy based on blinded ABPM
measurements have been previously documented (Smith et
al 2003). The State Ethics Committee of Clinical Research
approved the study.
Clinic BP measurements (6 per study visit after being
seated for at least 5 minutes, on the same day just before
starting ABPM) were always obtained by the same
investigator with a validated automatic oscillometric device
(HEM-737, Omron Health Care Inc., Vernon Hills, Illinois,
USA) (Anwar et al 1998). Assignment of subjects to
treatment groups was done by one member of the research
team, according to the order of recruitment, following an
allocation table constructed by a computerized random-Therapeutics and Clinical Risk Management 2007:3(1) 124
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number generator. The assignment of subjects to the
respective treatment-time groups was blinded from the
research team member conducting the clinic BP
measurements and from those performing the statistical
analysis of the data.
ABPM assessment
The SBP, DBP, and HR of each participant were
automatically measured every 20 minutes from 07:00 to
23:00 and every 30 minutes during the night for 48
consecutive hours with a properly calibrated SpaceLabs
90207 device (SpaceLabs Inc., Issaquah, Washington, USA).
Subjects were studied by ABPM under baseline conditions
when subjects were free of medication (after washout in
previously treated subjects), and again after 3 months of
timed therapy. Participants were instructed to go about their
usual activities with minimal restrictions but to follow a
similar schedule during the two days of ABPM and to avoid
daytime napping. No one was hospitalized during
monitoring. ABPM always began between 10:00 and 12:00.
BP series were not considered valid for analysis if more
than 30% of the measurements were lacking or if they had
missing data for >2 h spans, or if they were collected from
subjects while experiencing an irregular rest-activity
schedule or a nighttime sleep span <6 h or >12 h during
monitoring. Protocol-correct data series were collected from
200 subjects and therefore included in this efficacy stuty.
Baseline BP profiles of 7 additional subjects (4 originally
assigned to morning treatment and 3 to bedtime treatment)
were eliminated because the patients failed to return for the
second ABPM at the end of treatment.
Actigraphy
During 48 h ABPM each participant wore a Mini-Motion-
Logger actigraph (Ambulatory Monitoring Inc., Ardsley,
New York, USA) on the dominant wrist to monitor physical
activity every minute. This compact (about half the size of
a wrist watch) device functions as an accelerometer. The
internal clocks of the actigraph and the ABPM devices were
synchronized through their respective interfaces by the same
computer. The actigraphy data were used to determine the
onset and offset times of diurnal activity and nocturnal sleep
so as to accurately determine the diurnal and nocturnal BP
means of each subject. The mean activity for the 5 minutes
before each BP reading was then calculated for further
statistical analysis on circadian variability of activity,
according to previous studies on this area (Mansoor et al
2000; Hermida et al 2002a).
Statistical methods
Each individual’s clock hour BP and HR values were first
re-referenced from clock time to hours after awakening from
nocturnal sleep, according to the information obtained from
wrist actigraphy. This transformation avoided the
introduction of bias due to differences among subjects in
their sleep/activity routine (Hermida et al 2002a). BP and
HR time series were then edited according to conventional
criteria to remove measurement errors and outliers (Staessen
et al 1991). Thus, readings with SBP >250 mm Hg or
<70 mm Hg, DBP >150 mm Hg or <40 mm Hg, and pulse
pressure (PP, difference between SBP and DBP) >150 mm
Hg or <20 mm Hg were automatically discarded. For
descriptive purposes, the circadian rhythm of BP, HR, and
wrist activity before and after 3 months of intervention was
objectively assessed by population multiple-component
analysis (Fernández and Hermida 1998), a method
applicable to nonsinusoidal shaped hybrid time series data
(time series collected from a group of subjects) consisting
of values distributed at equal or unequal intervals. The
circadian rhythm parameters of MESOR (average value of
the rhythmic function fitted to the data), overall amplitude
(one-half the difference between the maximum and the
minimum values of the best fitted curve), and orthophase
(peak time, expressed as a lag from the time of awakening
from nocturnal sleep) obtained for each group of patients
before and after intervention were compared with a paired
nonparametric test developed to assess differences in
parameters derived from population multiple-components
analysis (Fernández et al 2004). Hourly BP means obtained
before and after intervention were compared by t-test
corrected for multiple testing with the Holm procedure
(Holm 1979). The daily (24 h), diurnal, and nocturnal means
of BP were further compared among treatment groups by
ANOVA.
Results
Efficacy with valsartan on awakening
The circadian rhythm of SBP and DBP before and after
treatment with valsartan on awakening is depicted in Figures
1 and 2 (left graphs). Morning valsartan treatment resulted
in a statistically significant reduction in BP from baseline
after 3 months of treatment (13.0 mm Hg and 8.1 mm Hg
reduction in the 24 h mean of SBP and DBP, respectively;
p<0.001). After treatment, 66% of the patients had a
controlled diurnal BP (below 135/85 mm Hg), but only 33%
had a controlled nocturnal BP (below 120/70 mm Hg). There
was also a significant reduction (p<0.001) of 4.8 mm Hg inTherapeutics and Clinical Risk Management 2007:3(1) 125
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Figure 1 Circadian pattern of systolic blood pressure (SBP) before and after valsartan (160 mg/day) administered on awakening (left) or at bedtime (right) in
nondipper patients (n=100) with grade 1 or 2 essential hypertension studied by 48 h ambulatory monitoring. Each graph shows hourly means and standard errors
(SEs) of data collected before (continuous line) and after (dashed line) 3 months of treatment. Dark shading along the lower horizontal axis of the graphs represents
average hours of nocturnal sleep across the patients. Nonsinusoidal-shaped curves represented around means and SEs correspond to the best-fitted waveform model
determined by population multiple-component analysis. Arrows descending from upper horizontal axis point to the circadian orthophase (rhythm crest time).
Figure 2 Circadian pattern of dystolic blood pressure (DBP) before and after valsartan (160 mg/day) administered on awakening (left) or at bedtime (right) in non-
dipper patients (n=100) with grade 1 or 2 essential hypertension studied by 48 h ambulatory monitoring. Each graph shows hourly means and standard errors (SEs)
of data collected before (continuous line) and after (dashed line) 3 months of treatment. Dark shading along the lower horizontal axis of the graphs represents
average hours of nocturnal sleep across the patients. Nonsinusoidal-shaped curves represented around means and SEs correspond to the best-fitted waveform model
determined by population multiple-component analysis. Arrows descending from upper horizontal axis point to the circadian orthophase (rhythm crest time).
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the 24 h mean of PP when valsartan was administered on
awakening. Figures 1 and 2 (left panels) indicate a
homogeneous BP reduction during the 24 h after treatment.
These graphs further indicates that the mean reduction in
BP at each clock time during the 24 h dosing interval was
statistically significant (p always <0.001 after correcting
for multiple testing), as designated by the asterisks above
the lower horizontal axis. Despite the significant reduction
in BP, there was no effect of valsartan on HR (decrease in
the 24 h mean of 0.2 beats/minute, p=0.782 compared with
baseline; not shown). The circadian pattern of physical
activity monitored before and after 3 months of treatment
also remained unchanged.
Efficacy with valsartan at bedtime
The graphs on the right of Figures 1 and 2 show the
significant reduction compared with baseline of 15.2 mm
Hg and 10.6 mm Hg in the 24 h mean of SBP and DBP,
respectively (p<0.001) after 3 months of 160 mg/d valsartan
taken at bedtime. After treatment, 76% of the patients had a
controlled diurnal BP, and 59% had a controlled nocturnal
BP. The 24 h mean of PP was also significantly reduced
from baseline by 4.8 mm Hg (p<0.001). HR remained
unchanged after 3 months of treatment (increase in the 24 h
mean of 0.9 beats/minute, p=0.122). The circadian pattern
of activity measured by wrist actigraphy was also similar
before and after 3 months of therapy.
Comparison between groups
The comparison of results shown in Figures 1 and 2 revealed
lack of statistically significant differences in ambulatory BP
at baseline among the 2 treatment groups. After 3 months
of timed treatment, the 24 h mean BP was also similar for
both groups; accordingly, the treatment efficacy of valsartan
on the 24 h of BP was comparable and independent of the
time of its administration. The effect of medication on the
nocturnal mean of BP was, however, significantly greater
when valsartan was administered at bedtime. Figure 3
provides additional information on the comparison between
the treatment groups of the changes in the diurnal, nocturnal,
and 24 h mean BP values after 3 months of therapy. Figure
3 reveals the significant difference between the treatment-
groups in the effect of valsartan on the nocturnal mean of
SBP and DBP (p<0.001).
When valsartan was taken on awakening, the mean
reduction in the diurnal and nocturnal BP means was similar
(Figure 3). However, when valsartan was taken at bedtime,
the mean reduction in nocturnal BP was significantly greater
than the mean reduction in diurnal BP. Accordingly, there
was a statistically significant average increase (p<0.001)
by 7.2% in the nocturnal decline in BP relative to the diurnal
mean (an index of the BP dipping) only when valsartan was
taken at bedtime (Figure 4), which resulted in 76% of the
patients in this group reverted to a dipper BP pattern after 3
months of treatment.
Discussion
This prospective randomized trial focused on the potential
benefits of chronotherapy in the specific treatment of non-
dipper hypertensive patients. Results, extending and
complementing a previous trial on the general hypertensive
population (Hermida et al 2003a), indicate that 160 mg/day
valsartan provide 24 h coverage when taken once daily either
upon awakening or at bedtime. Valsartan, no matter the
treatment time, also significantly reduced PP, a marker of
cardiovascular risk. Valsartan dosing upon awakening and
at bedtime similarly reduced BP during the 24 h (Figure 3);
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Figure 3 Effects on the diurnal, nocturnal, and 24 h mean of systolic blood
pressure (SBP) (top) and dystolic blood pressure (DBP) (bottom) of valsartan
(160 mg/day) administered on awakening or at bedtime in nondipper patients
with grade 1 or 2 essential hypertension studied by 48 h ambulatory monitoring
before and after 3 months of treatment. Probability values are shown for
comparison of effects between the 2 groups of subjects by ANOVA.Therapeutics and Clinical Risk Management 2007:3(1) 127
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however, valsartan when administered at bedtime was
especially efficient in reducing nocturnal BP and thus
significantly increasing the diurnal/nocturnal ratio of BP
(Figure 4). While in the general population (Hermida et al
2003a) the effects of treatment in nocturnal mean of BP
were not statistically different between morning and bedtime
dosing of valsartan, results in Figure 3 indicate that, in
nondipper patients, the efficacy of valsartan at bedtime on
the nocturnal mean of BP increases by 70% as compared
with morning dosing. Other studies have also found
differential effects of antihypertensive treatment between
dipper and nondipper patients (Ebata et al 1995; Kario and
Shimada 1997; Kohno et al 1999, 2000; Kario et al 2000).
Nocturnal hypertension, which is characterized by the
loss or even reversal of the expected 10%–20% sleep-time
BP decline, increases one’s risk of cardiovascular and
cerebrovascular events, nephrosclerosis, and progression to
end-stage kidney failure in renal patients. Normalization of
the circadian BP rhythm is considered to be an important
clinical goal of pharmacotherapy because it may slow the
advance of renal injury and avert end-stage renal failure
(Timio et al 1993; Bianchi et al 1994). Nondipper BP
patterning is more frequent in hypertension that is secondary
to specific medical conditions, such as chronic renal failure,
diabetes and autonomic nervous system dysfunction, than
in uncomplicated primary hypertension (Hermida et al
2002). Results from a recent study, however, indicate a high
38% prevalence of nondipping among untreated patients
with essential hypertension (Hermida et al 2002a). Most
important, the percentage of nondipper patients significantly
increase to 62% when they are evaluated by 48 h ABPM
under the effect of antihypertensive therapy. The percentage
of patients who were receiving all their antihypertensive
drugs in a single morning dose was significantly larger
among nondippers (91%) as compared with dippers (59%),
thus suggesting that nondipping among treated patients is
partly due to the lack of 24 h therapeutic coverage of many
antihypertensive drugs used in single morning dosing.
The definition of nocturnal hypertension on the basis of
the dipper concept has been frequently criticized due to the
inability to reproduce over time the classification of patients
into dippers and nondippers (Mochizuki et al 1998). This
may partly be due to the fact that most studies relied on 24 h
monitoring. The advantages of 48 h sampling, instead of
the most common 24 h ABPM, in terms of reproducibility
of results and classification have been documented
previously (Mochizuki et al 1998; Hermida et al 2002a,
2002c). Uncertainty in the classification of a patient as
Figure 4 Effects on the relative nocturnal BP decline with respect to the diurnal mean (diurnal/nocturnal ratio) of valsartan (160 mg/day) administered on awakening
or at bedtime in nondipper patients with grade 1 or 2 essential hypertension studied by 48 h ambulatory monitoring before and after 3 months of treatment. P values
on top are shown for comparison of effects among the 2 groups of patients by ANOVA. P values on the bottom are shown for the change in diurnal/nocturnal ratio
after treatment for every group and variable by paired t-test.
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dipper may be reduced from 42% to just 6% by expanding
monitoring from 24 h to 48 h (Hermida et al 2002b), as the
proper estimation of mean BP values is more dependent on
duration of monitoring than on sampling rate (Hermida and
Ayala 2003).
International guidelines recommend the use of long-
acting, once-daily medications that provide 24 h efficacy;
they improve adherence to therapy and minimize BP
variability with with smoother and more consistent BP
control (Chobanian et al 2003; Guidelines Committee 2003).
Most antihypertensive medication, including valsartan, has
been approved to be used once-daily, without any
specification of treatment-time. Use of a medication with a
high homogeneous efficacy along the 24 h, such as
amlodipine or valsartan administered on awakening, is
unlikely to affect the circadian profile of BP and may be the
best choice for the treatment of dipper hypertensive patients.
This therapeutic scheme, however, may not be appropriate
for managing nondippers, since it is important to avoid
nocturnal hypertension (Staessen et al 1999; Kikuya et al
2005). The available scientific evidence suggests nondippers
may benefit from evening dosing of certain BP-lowering
medications to reduce abnormally high BP and to convert
the disturbed 24 h BP profile to normal dipper pattern of
lower cardiovascular risk. However, because the effects of
BP medications can be circadian stage dependent, the
specific administration-time-dependent dose-response curve
of the drug must be determined and taken into consideration
to treat hypertensive patients effectively. The most recent
studies on the chronotherapy of hypertension summarized
here confirm the effects of antihypertensive medications can
vary, sometimes dramatically, as a function of their circadian
time of dosing.
The potential reduction in cardiovascular risk associated
with the normalization of the circadian variability of BP
(converting a nondipper to dipper BP pattern) is still a matter
of debate. Apart from the Syst-Eur trial where nitrendipine
was administered at bedtime, results from the HOPE
substudy where patients were evaluated by ABPM indicated
a significant BP reduction mainly during hours of nighttime
sleep (Svensson et al 2001). The authors suggested that the
beneficial effects on cardiovascular morbidity and mortality
in the HOPE study may be related to the 8% increase in the
diurnal/nocturnal ratio of BP seen after ramipril was
administered at bedtime. A recent study with another ACEI,
temocapril, evaluated its time-dependent effect on the
mortality of stroke-prone spontaneous hypertensive rats
(Nozawa et al 2006). Temocapril prolonged the survival rate
of the animals, with a maximum effect after dosing at the
early resting period and a minimal effect after dosing at the
early active period. These results are relevant inasmuch as,
similarly to other ACEI, morning dosing with temocapril
significantly reduces diurnal BP to a greater extent than
nocturnal BP and thus decreases the diurnal/nocturnal BP
ratio towards a more nondipper profile (Eguchi et al 2002).
Another relevant study where the nondipper BP profile
in patients with chronic renal failure was normalized after
evening but not after morning four-week dosing of isradipine
(Portaluppi et al 1995) did not conduct follow-up to evaluate
potential changes in cardiovascular risk, mainly due to the
short period of active treatment. On the other hand, recent
results have demonstrated that urinary albumin excretion
was significantly reduced after bedtime, but not morning,
treatment with valsartan (Hermida et al 2005e). This
reduction was independent of the 24 h BP decrease after
treatment, but highly correlated with the decrease in the
nocturnal mean of BP and, mainly, with the increase in
diurnal/nocturnal BP ratio associated with bedtime
administration of valsartan. These results are of clinical
importance, as there is growing evidence that reduction of
urinary albumin excretion provides renal protection and
reduces cardiovascular risk (Ruggenenti et al 2001).
Apart from this beneficial effect of chronotherapy on
albumin, plasma fibrinogen has also been shown to be
significantly reduced after bedtime treatment with valsartan
in direct correlation with the increasing diurnal/nocturnal
BP ratio resulting from the conversion of nondippers into
dippers (Hermida et al 2005c, 2005e). Clinical trials and
epidemiological observations have indicated that elevated
plasma fibrinogen levels are strongly correlated with an
increased frequency of vascular events, thus recognizing
fibrinogen as a significant parameter for assessing the
potential risk of acute myocardial infarction and stroke
(Wilhelmsen et al 1984). Previous results have already
established that plasma fibrinogen is significantly elevated
in nondipper as compared with dipper hypertensives
(Hermida et al 2003b). The reduction in fibrinogen in
relation to the normalization of the BP profile, ie, conversion
from nondipper to a dipper pattern, seems to provide further
evidence of the potential reduction in cardiovascular risk
associated with the normalization of the circadian BP pattern
in hypertensive patients with altered nocturnal BP.
Common to all previous trials demonstrating the
increased cardiovascular risk in non-dippers (O´Brien et al
1988; Verdecchia et al 1994; Staessen et al 1999; Ohkubo
et al 2002) is that the prognostic significance of ABPM hasTherapeutics and Clinical Risk Management 2007:3(1) 129
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relied on a single baseline profile from each participant,
without accounting for possible changes in the BP pattern,
mainly associated with antihypertensive therapy and aging
during follow-up. Along these lines, the MAPEC study
(Monitorización Ambulatoria de Presión arterial y Eventos
Cardiovasculares) was designed to investigate whether
normalizing the circadian BP profile towards a more dipper
pattern by chronotherapy strategies reduces cardiovascular
risk (Hermida et al 2006). This prospective study
investigates over 2600 subjects from the health registry of
Santiago de Compostela (Northwest Spain). At inclusion,
BP was measured for 48 consecutive hours at 20-minute
intervals from 07:00 to 23:00 and at 30-minute intervals at
night. Physical activity was simultaneously monitored every
minute by wrist actigraphy. Blood samples and 24 h urine
collection were obtained the same day before starting
ABPM. The same evaluation procedure is scheduled yearly
(or more frequently, every three months, if treatment
adjustment is required). Based on the baseline ABPM and
after a median time of follow-up of 3.2 years, cardiovascular
morbidity was similar for extreme-dippers (diurnal/nocturnal
BP ratio >20%; 1.23 events per 100 patient-years) and
dippers (1.14), but significantly higher for nondippers (2.81)
and mainly for risers (patients with nocturnal BP mean above
diurnal mean; 8.70 events per 100 patient-years). When
cardiovascular morbidity was analyzed on the basis of the
last ABPM profile closest to the cardiovascular event (or
the last available evaluation for event-free patients),
morbidity was found to be reduced in extreme-dippers (0.38)
and dippers (0.89), but increased in nondippers (3.23) and
risers (10.70). All cases but one of cardiovascular death were
associated with a riser or nondipper pattern prior to the event
(Hermida et al 2006). Results from this ongoing prospective
study indicate the probability of event-free survival is
strongly correlated with the diurnal/nocturnal BP ratio. Most
important, results suggest that increasing this ratio towards
a more dipper pattern decreases cardiovascular risk, while
decreasing the diurnal/nocturnal BP ratio is associated with
increased morbidity and mortality. In the light of all these
findings, evaluation of the potential decrease in
cardiovascular risk from the proper modeling of the
circadian BP profile by the timed administration of
antihypertensive medication, beyond reduction of BP levels,
deserves further prospective investigation.
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